Author: jameshebrew

T-Cell immunotherapies have gained a lot of traction in recent years. With a plethora of clinical evidence and billions of dollars in investment, calling T-cell therapies as the next big... Read More

Novel Cancer is known to be one of the leading causes of death worldwide, accounting for more than 600,000 deaths in 2018 in the US alone. As per the recent... Read More

"The Super Generics industry has enjoyed a remarkable run over the past two decades. The vast healthcare cost-saving potential of these therapies has accelerated their adoption and proven the immense potential that... Read More

After the immense success of PARP inhibitors at ESMO 2019, synthetic lethality has become the talk of the town. From industry analysts to healthcare researchers, everyone is now interested in... Read More